About: DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Sector: Healthcare
Industry: Biotechnology
Latest price: $9.80 (-0.25%)
DMAC NASDAQ DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc share price
Atividade de preço de DMAC
Último preço
$ 9,800
Variação (24h)
-0,03 USD (0,25%)
Volume
45.79K
Volume (média 4 sem.)
-
Abertura
$ 9,83
Variação do dia
$ 9,77 - $ 9,99
Fechamento anterior
$ 9,82
Último negócio
29 Oct, 3:01 pm GMT+0
Atrasado
29 Oct, 3:01 pm GMT+0
DMAC price performance
Atrasado
29 Oct, 3:01 pm GMT+0
quote.marketSignals